Anavex Life Sciences Corp. The company is headquartered in New York, New York.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -30.80% |
| Return on Assets | -19.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.31 |
| Price-to-Book | 2.46 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -5.54 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $92.70M |
| Float | $89.79M |
| % Insiders | 1.71% |
| % Institutions | 40.65% |
Volatility is currently contracting
Launches VoteAnavex.com to Provide Additional Information on Anavex's Director Nominees and How to Vote at the Annual Meeting of Stockholders
Nominates Two New Independent Directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, Who Bring Deep, Relevant Experience in Life Sciences
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) diseases with high unmet medical needs, today reported preliminary financial results for its fiscal second quarter ended March 31, 2026. The Company's primary focus is on advancing its lead compound ANAVEX®2-73 (blarcamesine) in the Company's clinical program for the treatment of mild cognitive impairment (“MCI”) due to Alzheimer's disease (“AD”) and mild AD (collectively known as “early AD”), and for Rett syndrome and Fragile X syndrome, both of which are neurodevelopmental rare diseases.
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, today announced it received an expected delinquency notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 20, 2026. The Notice indicates that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Nasdaq Listing Rule”) as a result of the Company's inability to timely file its Form 10-Q for the quarterly period ended March 31, 2026.
Findings underpin the scientific rationale for Anavex's targeted autophagy approach with orally administered blarcamesine
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 25th Annual Needham Virtual Healthcare Conference, April 13 – 16, 2026. President and Chief Executive Officer Christopher U. Missling, PhD and his management team will present the Company scheduled at 1:30 PM (ET) on Tuesday, April 14th, 2026.
This decision follows feedback from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), which indicated it would not issue a positive opinion at this time.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AVXL and any ticker you trade — then tracks every position and per-strategy win rate.
